- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports First Quarter 2024 Financial Results
- EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
- EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
- EQS-NVR: MorphoSys AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
More ▼
Key statistics
On Thursday, MorphoSys AG (1MOR:MIL) closed at 67.45, -15.26% below its 52-week high of 79.60, set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 69.10 |
Average volume | 8.50 |
---|---|
Shares outstanding | 37.72m |
Free float | 31.88m |
P/E (TTM) | -- |
Market cap | 2.62bn EUR |
EPS (TTM) | -12.54 EUR |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼